Summary
1.70 -0.06(-3.41%)09/27/2024
180 Life Sciences Corp (ATNF)
180 Life Sciences Corp (ATNF)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.96 | -13.71 | -10.99 | 11.84 | -15.42 | 188.14 | -83.81 | -82.47 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.70 | |
| Open | 1.84 | |
| High | 1.84 | |
| Low | 1.70 | |
| Volume | 31,300 | |
| Change | -0.07 | |
| Change % | -3.96 | |
| Avg Volume (20 Days) | 43,083 | |
| Volume/Avg Volume (20 Days) Ratio | 0.73 | |
| 52 Week Range | 0.15 - 4.80 | |
| Price vs 52 Week High | -64.58% | |
| Price vs 52 Week Low | 1,033.33% | |
| Range | -7.61 | |
| Gap Up/Down | -0.07 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 11.00 | |
| Book Value | 1.0930 | |
| Earnings Per Share | -1.0720 | |
| EPS Estimate Current Quarter | -0.1200 | |
| EPS Estimate Next Quarter | -0.1300 | |
| EPS Estimate Current Year | -0.8100 | |
| EPS Estimate Next Year | -0.5500 | |
| Diluted EPS (TTM) | -1.0720 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.2233 | |
| Return on equity (TTM) | -1.3907 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.7276 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 34,016,500 | |
| Shares Float | 24,021,401 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 32.92 | |
| Institutions (%) | 8.08 | |
09/12 16:15 EST - globenewswire.com
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors.
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors.
07/30 08:00 EST - globenewswire.com
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced topline results from a clinical pharmacology study (the “Study”), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic (PK) profile of a generic approved CBD product, Epidiolex®, with two solid formulations. We believe this type of trial has yet to be examined in a clinical setting. For the Company's trial, twelve volunteers received all three formulations in a crossover randomized trial.
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced topline results from a clinical pharmacology study (the “Study”), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic (PK) profile of a generic approved CBD product, Epidiolex®, with two solid formulations. We believe this type of trial has yet to be examined in a clinical setting. For the Company's trial, twelve volunteers received all three formulations in a crossover randomized trial.
07/02 08:30 EST - globenewswire.com
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has determined to grant the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below) and providing an indication of its equity following those transactions.
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has determined to grant the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below) and providing an indication of its equity following those transactions.
03/14 08:30 EST - globenewswire.com
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).
02/26 07:00 EST - globenewswire.com
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.
12/04 09:00 EST - globenewswire.com
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.
11/28 09:00 EST - globenewswire.com
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.
08/14 16:29 EST - globenewswire.com
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are approximately $3 million, before deducting the placement agent's fees and other offering expenses.
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are approximately $3 million, before deducting the placement agent's fees and other offering expenses.
08/10 08:46 EST - globenewswire.com
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are expected to be approximately $3 million, before deducting the placement agent's fees and other offering expenses.
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are expected to be approximately $3 million, before deducting the placement agent's fees and other offering expenses.
08/09 08:06 EST - investorplace.com
Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?
180 Life Sciences (NASDAQ: ATNF ) stock is climbing higher on Wednesday as the cannabis market undergoes a rally. The cannabis sector has been on the rise lately as several companies in it release earnings reports.
Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?
180 Life Sciences (NASDAQ: ATNF ) stock is climbing higher on Wednesday as the cannabis market undergoes a rally. The cannabis sector has been on the rise lately as several companies in it release earnings reports.
08/07 09:00 EST - globenewswire.com
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“Pharmacokinetic” or “PK”) study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally. The PK study will seek to determine how much CBD is taken up into the blood of volunteers.
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“Pharmacokinetic” or “PK”) study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally. The PK study will seek to determine how much CBD is taken up into the blood of volunteers.
05/21 06:00 EST - pennystocks.com
Penny Stock Investing, 3 High-Growth Industries to Watch
Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Investing, 3 High-Growth Industries to Watch
Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
05/19 12:57 EST - pennystocks.com
5 Top Penny Stocks To Watch Today; Time To Buy?
5 hot penny stocks to watch right now. The post 5 Top Penny Stocks To Watch Today; Time To Buy?
5 Top Penny Stocks To Watch Today; Time To Buy?
5 hot penny stocks to watch right now. The post 5 Top Penny Stocks To Watch Today; Time To Buy?
03/01 11:08 EST - businesswire.com
Elicit Plant beruft Pam Marrone und Johan de Saegher in den Vorstand
MOULINS-SUR-TARDOIRE, Frankreich--(BUSINESS WIRE)--Elicit Plant, ein Agro-Biotechnologieunternehmen, das sich auf die Resistenz von Nutzpflanzen gegen Wasserstress auf Basis einer phytosterolbasierten Technologieplattform spezialisiert hat, meldete heute die Ernennung von Dr. Pam Marrone zur Vorstandsvorsitzenden und von Dr. Johan de Saegher zum unabhängigen Vorstandsmitglied. Pam Marrone ist als Serial Entrepreneur eine Unternehmerin, die mehr als 30 Jahre Führungserfahrung in der Agrar-Biotechnologie-Branche vorweisen kann. Sie ist derzeit Vorstandsvorsitzende der Invasive Species Control Corporation, die sie im Jahr 2022 mitbegründet hat. In jüngster Zeit war sie als Chief Executive Officer bei Marrone Bio Innovations (MBI) tätig, einem Agro-Biotechnologie-Unternehmen, das sie 2006 gründete. Im Jahr 2013 ging MBI an die US-amerikanische Technologiebörse NASDAQ. Unter ihrer Führung brachte das Unternehmen zehn Produkte mit sechs bei der US-Umweltschutzbehörde EPA registrierten Wirkstoffen auf den Markt und übernahm 2019 das Unternehmen ProFarm Technologies, das aus Holzreststoffen gewonnene biologische Nährstoffe für die Saatgutbehandlung vertreibt. 1995 gründete Pam Marrone das Unternehmen AgraQuest, wo sie bis 2006 als CEO, Vorstandsvorsitzende bzw. Präsidentin tätig war. Pam Marrone ist eine anerkannte Führungspersönlichkeit. Dies belegen zahlreiche Auszeichnungen wie beispielsweise der „Kathryn C. Hach Award for Entrepreneurial Success“ der American Chemical Society, die Auszeichnung als „Most Admired CEO, Distinguished Career Award“ des Sacramento Business Journal, der „Sustie Award“ der Ecological Farming Association und der „Growing Green Award“ des Natural Resources Defense Council (NRDC) in der Kategorie „Business Leader“. Darüber hinaus ist Pam Marrone Gründerin der Biological Products Industry Alliance, eines Fachverbands, dem heute mehr als 100 Unternehmen angehören. Neben ihrer Funktion als Vorstandsvorsitzende von Elicit Plant ist Marrone in den Vorständen mehrerer Unternehmen und gemeinnütziger Organisationen tätig, darunter 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym und die Foundation for Food and Agriculture Research. Johan de Saegher ist eine erfahrene Führungskraft. Er kann mehr als 30 Jahre Erfahrung in der Wirtschaft vorweisen, von denen er 17 Jahre in der Pflanzenschutzbranche tätig war. Derzeit ist er CEO von Bi-PA, einem Unternehmen, das sich auf die Entwicklung innovativer Lösungen zur Schädlingsbekämpfung spezialisiert hat. Von 2018 bis 2022 bekleidete er die Position des CEO und COO von Belchim Crop Protection NV, einem führenden europäischen Vertriebsunternehmen im Pflanzenschutzmarkt mit Sitz in Belgien, das auch in Nordamerika und Asien aktiv ist. Zuvor und bis zur Übernahme des Unternehmens durch Eastman Chemical im Jahr 2014 war de Saegher bei Taminco (NYSE) als Chief Operating Officer, Vice President für den Bereich Agrosciences und President für die Region Asien/Lateinamerika tätig. Derzeit ist er außerdem Chairman von Aphea.bio und Vorstandsmitglied bei Mitsui Agrisciences International. „Mich haben die hervorragenden Ergebnisse, die Elicit Plant in so kurzer Zeit erzielt hat, sehr beeindruckt. Die beispiellose Technologieplattform des Unternehmens wirkt sich positiv auf unsere Erde aus und bietet Landwirten eine natürliche, effiziente Lösung als Antwort auf die Herausforderungen des Klimawandels. Ich freue mich darauf, mit dem Team zusammenzuarbeiten und mit ihm das Wachstum des Unternehmens zu beschleunigen“, so Pam Marrone. Johan de Saegher ergänzte dies folgendermaßen: „Es ist mir eine große Ehre, dem Vorstand von Elicit Plant beizutreten und dazu beitragen zu können, das Unternehmen in seiner nächsten Entwicklungsphase zu einem profitablen Großunternehmen zu machen. Mit seinen hochwertigen Lösungen für Reihenkulturen eröffnet Elicit Plant eine neue Dimension im Umgang mit abiotischem Stress, wie z. B. Trockenheit, und schützt die Erträge der Landwirte, indem die natürliche Reaktion der Pflanzen auf die sich verändernden Umweltbedingungen optimiert wird.“ Jean-François Dechant, Chief Executive Officer und Mitbegründer von Elicit Plant, äußerte sich hierzu wie folgt: „Pam Marrone und Johan de Saegher ergänzen unser Unternehmen auf hervorragende Weise. Elicit Plant erschließt derzeit neue Märkte, erweitert seine Labors und diversifiziert sein Produktportfolio. In dieser für Elicit Plant strategisch wichtigen Zeit bedanken wir uns für ihr Vertrauen und freuen uns darauf, von ihrem Wissen und von ihrer beeindruckenden Erfolgsbilanz zu profitieren.“ Über Elicit Plant Elicit Plant ist ein 2017 mit dem Ziel gegründetes Agro-Biotechnologieunternehmen, ein Spitzenreiter im Bereich der Umstellung auf Nachhaltigkeit in der Landwirtschaft zu werden und auf die globalen Herausforderungen des Wasserstresses bei Nutzpflanzen zu reagieren. Das im französischen Charente ansässige Unternehmen beschäftigt in seinem F&E-Zentrum auf einer 1.000 ha großen Farm, in seinen Büros in Lyon und bei seiner Tochtergesellschaft in Brasilien 60 Mitarbeitende. Die proprietäre Technologie von Elicit Plant wird über die Blattapplikation von Phytosterolen angewandt, d. h. von in den Pflanzen vorkommenden Molekülen, die den Wasserverbrauch der Kulturpflanzen reduzieren. Feldversuche ergaben eine durchschnittliche Ertragssteigerung von 10 Bushel pro Acre. 2022 begann Elicit Plant mit der Vermarktung seiner Produktlinie BEST-a für Maiskulturen in Frankreich und bekam die Marktzulassung für die Ukraine und Brasilien. Weitere Informationen erhalten Sie unter: www.elicit-plant.com Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
Elicit Plant beruft Pam Marrone und Johan de Saegher in den Vorstand
MOULINS-SUR-TARDOIRE, Frankreich--(BUSINESS WIRE)--Elicit Plant, ein Agro-Biotechnologieunternehmen, das sich auf die Resistenz von Nutzpflanzen gegen Wasserstress auf Basis einer phytosterolbasierten Technologieplattform spezialisiert hat, meldete heute die Ernennung von Dr. Pam Marrone zur Vorstandsvorsitzenden und von Dr. Johan de Saegher zum unabhängigen Vorstandsmitglied. Pam Marrone ist als Serial Entrepreneur eine Unternehmerin, die mehr als 30 Jahre Führungserfahrung in der Agrar-Biotechnologie-Branche vorweisen kann. Sie ist derzeit Vorstandsvorsitzende der Invasive Species Control Corporation, die sie im Jahr 2022 mitbegründet hat. In jüngster Zeit war sie als Chief Executive Officer bei Marrone Bio Innovations (MBI) tätig, einem Agro-Biotechnologie-Unternehmen, das sie 2006 gründete. Im Jahr 2013 ging MBI an die US-amerikanische Technologiebörse NASDAQ. Unter ihrer Führung brachte das Unternehmen zehn Produkte mit sechs bei der US-Umweltschutzbehörde EPA registrierten Wirkstoffen auf den Markt und übernahm 2019 das Unternehmen ProFarm Technologies, das aus Holzreststoffen gewonnene biologische Nährstoffe für die Saatgutbehandlung vertreibt. 1995 gründete Pam Marrone das Unternehmen AgraQuest, wo sie bis 2006 als CEO, Vorstandsvorsitzende bzw. Präsidentin tätig war. Pam Marrone ist eine anerkannte Führungspersönlichkeit. Dies belegen zahlreiche Auszeichnungen wie beispielsweise der „Kathryn C. Hach Award for Entrepreneurial Success“ der American Chemical Society, die Auszeichnung als „Most Admired CEO, Distinguished Career Award“ des Sacramento Business Journal, der „Sustie Award“ der Ecological Farming Association und der „Growing Green Award“ des Natural Resources Defense Council (NRDC) in der Kategorie „Business Leader“. Darüber hinaus ist Pam Marrone Gründerin der Biological Products Industry Alliance, eines Fachverbands, dem heute mehr als 100 Unternehmen angehören. Neben ihrer Funktion als Vorstandsvorsitzende von Elicit Plant ist Marrone in den Vorständen mehrerer Unternehmen und gemeinnütziger Organisationen tätig, darunter 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym und die Foundation for Food and Agriculture Research. Johan de Saegher ist eine erfahrene Führungskraft. Er kann mehr als 30 Jahre Erfahrung in der Wirtschaft vorweisen, von denen er 17 Jahre in der Pflanzenschutzbranche tätig war. Derzeit ist er CEO von Bi-PA, einem Unternehmen, das sich auf die Entwicklung innovativer Lösungen zur Schädlingsbekämpfung spezialisiert hat. Von 2018 bis 2022 bekleidete er die Position des CEO und COO von Belchim Crop Protection NV, einem führenden europäischen Vertriebsunternehmen im Pflanzenschutzmarkt mit Sitz in Belgien, das auch in Nordamerika und Asien aktiv ist. Zuvor und bis zur Übernahme des Unternehmens durch Eastman Chemical im Jahr 2014 war de Saegher bei Taminco (NYSE) als Chief Operating Officer, Vice President für den Bereich Agrosciences und President für die Region Asien/Lateinamerika tätig. Derzeit ist er außerdem Chairman von Aphea.bio und Vorstandsmitglied bei Mitsui Agrisciences International. „Mich haben die hervorragenden Ergebnisse, die Elicit Plant in so kurzer Zeit erzielt hat, sehr beeindruckt. Die beispiellose Technologieplattform des Unternehmens wirkt sich positiv auf unsere Erde aus und bietet Landwirten eine natürliche, effiziente Lösung als Antwort auf die Herausforderungen des Klimawandels. Ich freue mich darauf, mit dem Team zusammenzuarbeiten und mit ihm das Wachstum des Unternehmens zu beschleunigen“, so Pam Marrone. Johan de Saegher ergänzte dies folgendermaßen: „Es ist mir eine große Ehre, dem Vorstand von Elicit Plant beizutreten und dazu beitragen zu können, das Unternehmen in seiner nächsten Entwicklungsphase zu einem profitablen Großunternehmen zu machen. Mit seinen hochwertigen Lösungen für Reihenkulturen eröffnet Elicit Plant eine neue Dimension im Umgang mit abiotischem Stress, wie z. B. Trockenheit, und schützt die Erträge der Landwirte, indem die natürliche Reaktion der Pflanzen auf die sich verändernden Umweltbedingungen optimiert wird.“ Jean-François Dechant, Chief Executive Officer und Mitbegründer von Elicit Plant, äußerte sich hierzu wie folgt: „Pam Marrone und Johan de Saegher ergänzen unser Unternehmen auf hervorragende Weise. Elicit Plant erschließt derzeit neue Märkte, erweitert seine Labors und diversifiziert sein Produktportfolio. In dieser für Elicit Plant strategisch wichtigen Zeit bedanken wir uns für ihr Vertrauen und freuen uns darauf, von ihrem Wissen und von ihrer beeindruckenden Erfolgsbilanz zu profitieren.“ Über Elicit Plant Elicit Plant ist ein 2017 mit dem Ziel gegründetes Agro-Biotechnologieunternehmen, ein Spitzenreiter im Bereich der Umstellung auf Nachhaltigkeit in der Landwirtschaft zu werden und auf die globalen Herausforderungen des Wasserstresses bei Nutzpflanzen zu reagieren. Das im französischen Charente ansässige Unternehmen beschäftigt in seinem F&E-Zentrum auf einer 1.000 ha großen Farm, in seinen Büros in Lyon und bei seiner Tochtergesellschaft in Brasilien 60 Mitarbeitende. Die proprietäre Technologie von Elicit Plant wird über die Blattapplikation von Phytosterolen angewandt, d. h. von in den Pflanzen vorkommenden Molekülen, die den Wasserverbrauch der Kulturpflanzen reduzieren. Feldversuche ergaben eine durchschnittliche Ertragssteigerung von 10 Bushel pro Acre. 2022 begann Elicit Plant mit der Vermarktung seiner Produktlinie BEST-a für Maiskulturen in Frankreich und bekam die Marktzulassung für die Ukraine und Brasilien. Weitere Informationen erhalten Sie unter: www.elicit-plant.com Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
03/01 05:30 EST - businesswire.com
Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors
MOULINS-SUR-TARDOIRE, France--(BUSINESS WIRE)--Elicit Plant, an agricultural biotechnology company specialized in crops’ resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member. Pam is a serial entrepreneur bringing over 30 years of leadership experience in the agricultural biologicals industry. Pam currently serves as Executive Chair of Invasive Species Control Corporation which she cofounded in 2022. Recently, she was Chief Executive Officer of Marrone Bio Innovations (MBI), an agricultural biological company she founded in 2006. In 2013, MBI listed its stock on NASDAQ. Under her leadership, the company commercialized 10 products from six EPA-registered active ingredients, and in 2019 acquired ProFarm Technologies selling bionutrient seed treatments from wood waste. Prior to establishing MBI, Marrone founded AgraQuest in 1995, where she served as CEO, Chairwoman or President until 2006. Pam is a well-recognized leader as evidenced by numerous awards, including the American Chemical Society’s “Kathryn C. Hach Award for Entrepreneurial Success,” “Most Admired CEO, Distinguished Career Award” by the Sacramento Business Journal, the “Sustie” award by the Ecological Farming Association, and the Natural Resources Defense Council (NRDC) Growing Green Award in the “Business Leader” category. Pam is the founder of the Biological Products Industry Alliance, now a trade group of more than 100 companies. Aside from her role as Chairwoman of Elicit Plant, Pam serves on several for-profit and non-profit Boards, including 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym and the Foundation for Food and Agriculture Research. Johan de Saegher is an accomplished business executive with 30 years of business experience of which 17 years in the crop protection industry. He currently serves as CEO of Bi-PA, a company specialized in developing innovative solutions for pest management. From 2018 to 2022 he held the position of CEO and COO of Belchim Crop Protection NV, a leading European distributor in the crop protection market, based in Belgium, with also activities in North America and Asia. Previously, and until the company was acquired by Eastman Chemical in 2014, Johan worked at Taminco (NYSE) where he held positions as Chief Operating Officer, Vice-President Agrosciences and President Asia/Latin America. He is currently also Chairman of Aphea.bio and holds a board position within Mitsui Agrisciences International. “I am impressed by the excellent achievements Elicit Plant has accomplished in such a short time. The company’s unique technology platform positively impacts the planet and provides farmers with a natural and efficient solution to address the challenges of climate change. I am looking forward to work alongside the team as it accelerates its growth,” said Pam Marrone. Johan de Saegher added, “It is an honor to join Elicit Plant’s Board of Directors and contribute to building the company into a large scale and profitable enterprise as it is entering its next phase of development. Through its high value solutions, Elicit Plant offers for row crops a new dimension in abiotic stress management such as drought, safeguarding the yield of the farmer by optimizing the natural response of the plants to the changing environment.” Jean-François Dechant, Chief Executive Officer and Cofounder of Elicit Plant, said: “Pam and Johan are a wonderful addition as Elicit Plant is entering new markets, expanding its laboratories and diversifying its portfolio of products. At such a strategic time for Elicit Plant, we are grateful for their confidence, and we are all eager to benefit from their knowledge and impressive track records.” About Elicit Plant Elicit Plant is an agbiotech company created in 2017 with the ambition to become a sustainability transition champion in agriculture and respond to the global challenges of water stress in crops. Based in Charente (France), the firm has 60 employees across its R&D Center established within a 1,000 ha farm, its offices in Lyon, and its subsidiary in Brazil. Elicit Plant’s proprietary technology is delivered through foliar application of phytosterols, molecules found in plants that reduce crops’ water consumption. Open-field trials have shown an average yield increase of +10 bushels per acre on average. In 2022, Elicit Plant began marketing its BEST-a product line for corn crops in France, and obtained market approvals for Ukraine and Brazil. For more information: www.elicit-plant.com
Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors
MOULINS-SUR-TARDOIRE, France--(BUSINESS WIRE)--Elicit Plant, an agricultural biotechnology company specialized in crops’ resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member. Pam is a serial entrepreneur bringing over 30 years of leadership experience in the agricultural biologicals industry. Pam currently serves as Executive Chair of Invasive Species Control Corporation which she cofounded in 2022. Recently, she was Chief Executive Officer of Marrone Bio Innovations (MBI), an agricultural biological company she founded in 2006. In 2013, MBI listed its stock on NASDAQ. Under her leadership, the company commercialized 10 products from six EPA-registered active ingredients, and in 2019 acquired ProFarm Technologies selling bionutrient seed treatments from wood waste. Prior to establishing MBI, Marrone founded AgraQuest in 1995, where she served as CEO, Chairwoman or President until 2006. Pam is a well-recognized leader as evidenced by numerous awards, including the American Chemical Society’s “Kathryn C. Hach Award for Entrepreneurial Success,” “Most Admired CEO, Distinguished Career Award” by the Sacramento Business Journal, the “Sustie” award by the Ecological Farming Association, and the Natural Resources Defense Council (NRDC) Growing Green Award in the “Business Leader” category. Pam is the founder of the Biological Products Industry Alliance, now a trade group of more than 100 companies. Aside from her role as Chairwoman of Elicit Plant, Pam serves on several for-profit and non-profit Boards, including 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym and the Foundation for Food and Agriculture Research. Johan de Saegher is an accomplished business executive with 30 years of business experience of which 17 years in the crop protection industry. He currently serves as CEO of Bi-PA, a company specialized in developing innovative solutions for pest management. From 2018 to 2022 he held the position of CEO and COO of Belchim Crop Protection NV, a leading European distributor in the crop protection market, based in Belgium, with also activities in North America and Asia. Previously, and until the company was acquired by Eastman Chemical in 2014, Johan worked at Taminco (NYSE) where he held positions as Chief Operating Officer, Vice-President Agrosciences and President Asia/Latin America. He is currently also Chairman of Aphea.bio and holds a board position within Mitsui Agrisciences International. “I am impressed by the excellent achievements Elicit Plant has accomplished in such a short time. The company’s unique technology platform positively impacts the planet and provides farmers with a natural and efficient solution to address the challenges of climate change. I am looking forward to work alongside the team as it accelerates its growth,” said Pam Marrone. Johan de Saegher added, “It is an honor to join Elicit Plant’s Board of Directors and contribute to building the company into a large scale and profitable enterprise as it is entering its next phase of development. Through its high value solutions, Elicit Plant offers for row crops a new dimension in abiotic stress management such as drought, safeguarding the yield of the farmer by optimizing the natural response of the plants to the changing environment.” Jean-François Dechant, Chief Executive Officer and Cofounder of Elicit Plant, said: “Pam and Johan are a wonderful addition as Elicit Plant is entering new markets, expanding its laboratories and diversifying its portfolio of products. At such a strategic time for Elicit Plant, we are grateful for their confidence, and we are all eager to benefit from their knowledge and impressive track records.” About Elicit Plant Elicit Plant is an agbiotech company created in 2017 with the ambition to become a sustainability transition champion in agriculture and respond to the global challenges of water stress in crops. Based in Charente (France), the firm has 60 employees across its R&D Center established within a 1,000 ha farm, its offices in Lyon, and its subsidiary in Brazil. Elicit Plant’s proprietary technology is delivered through foliar application of phytosterols, molecules found in plants that reduce crops’ water consumption. Open-field trials have shown an average yield increase of +10 bushels per acre on average. In 2022, Elicit Plant began marketing its BEST-a product line for corn crops in France, and obtained market approvals for Ukraine and Brazil. For more information: www.elicit-plant.com
03/01 05:30 EST - businesswire.com
Elicit Plant nomme Pam Marrone et Johan de Saegher à son Conseil d’administration
MOULINS-SUR-TARDOIRE, France--(BUSINESS WIRE)--Elicit Plant, une agri-biotech spécialisée dans la résistance des plantes au stress hydrique qui développe une plateforme technologique à base de phytostérols, annonce aujourd’hui la nomination à son Conseil d’administration de Dr. Pam Marrone en tant que Présidente et Dr. Johan de Saegher en tant que membre indépendant. Elicit Plant a été créée en 2017 avec l’ambition de l’ambition de devenir le champion français de la transition écologique pour l’agriculture. Sa plateforme technologique propriétaire fournit aux agriculteurs une solution innovante pour répondre aux défis mondiaux du changement climatique et de l’impact de la sécheresse sur les grandes cultures. Pam Marrone est une serial-entrepreneuse avec plus de 30 d’expérience dans le domaine des solutions biologiques pour l’agriculture. Actuellement, elle exerce en tant que Présidente exécutive de Invasive Species Control Corporation, entreprise qu’elle a cofondée en 2022. Précédemment, elle était Directrice Générale de Marrone Bio Innovations (MBI), une entreprise spécialisée dans l’agriculture bio qu’elle a créée en 2006. En 2013, MBI s’est introduite en bourse au Nasdaq aux Etats Unis. Sous sa direction, l’entreprise a commercialisé 10 produits issus de six ingrédients actifs enregistrés auprès de l’Agence de Protection Environnementale américaine (EPA), et en 2019 a racheté la société ProFarm Technologies spécialisée dans la commercialisation de bio-nutriments produits à partir de déchets de bois. Avant de créer MBI, Pam Marrone a fondé AgraQuest en 1995, entreprise au sein de laquelle elle a été Directrice générale puis Présidente jusqu’en 2006. Personnalité reconnue du secteur, Pam Marrone a été récompensée par de nombreux prix, tels que le “Kathryn C. Hach Award for Entrepreneurial Success,” décerné par l’American Chemical Society, le “Most Admired CEO, Distinguished Career Award” décérné par le Sacramento Business Journal, le prix “Sustie” attribué par l’Ecological Farming Association, et le “Growing Green Award” décerné par le Natural Resources Defense Council (NRDC). Pam Marrone a fondé le Biological Products Industry Alliance, une association professionnelle qui réunit aujourd’hui plus de 100 entreprises. A côté de son rôle de Présidente du Conseil d'administration d’Elicit Plant, Pam Marrone siège au Conseil d’administration de plusieurs entreprises et associations, tels que 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym et la Foundation for Food and Agriculture Research. Johan de Saegher apporte à Elicit Plant une expérience professionnelle de 30 ans dont 17 années dédiées à la protection des cultures agricoles. Il est aujourd’hui Directeur général de Bi-PA, une entreprise spécialisée dans le développement de solutions innovantes pour lutter contres contre les nuisibles agricoles. De 2018 à 2022, Johan de Saegher était Directeur général et Directeur des opérations de Belchim Crop Protection NV, un leader européen de la protection des cultures agricoles basé en Belgique, avec des activités en Amérique du Nord et en Asie. Précédemment, et jusqu’à ce que la société soit rachetée par Eastman Chemical en 2014, Johan de Saegher travaillait chez Taminco (NYSE) où il a successivement exercé les fonctions de Directeur des opérations, Vice-Président Agrosciences et Président Asie/Amérique Latine. Il est actuellement aussi Président de Aphea.bio et siège au Conseil d’administration de Mitsui Agrisciences International. « J’ai été impressionnée par le parcours qu’a réalisé Elicit Plant en si peu de temps. La plateforme technologique propriétaire qu’elle a développé fournit aussi aux agriculteurs une solution naturelle et efficace pour répondre aux défis du changement climatique tout en ayant un impact positif sur l’environnement. J’ai hâte de collaborer avec l’équipe au moment où l’entreprise accélère sa croissance », déclare Pam Marrone. Johan de Saegher poursuit : « C’est un honneur de rejoindre le Conseil d’administration d’Elicit Plant et contribuer à en faire un leader mondial. Grâce à sa technologie innovante, Elicit Plant ouvre de nouvelles perspectives dans le domaine de la gestion du stress abiotique, comme la sécheresse, et dans la protection des rendements agricoles grâce à une optimisation de la réponse naturelle des plantes aux transformations environnementales ». Jean-François Dechant, Président et cofondateur d’Elicit Plant, déclare : « L’arrivée de Pam et Johan est un atout formidable alors que nous nous déployons sur de nouveaux marchés, agrandissons nos laboratoires et diversifions notre portefeuille de produits. Dans une période si stratégique pour Elicit Plant, nous sommes reconnaissants de la confiance qu’ils nous accordent et ravis de la chance qui nous est donnée de bénéficier de leur savoir-faire et de leur track record exceptionnel ». A propos d’Elicit Plant Elicit Plant est une entreprise d’agri-biotech dont l’ambition est de devenir le champion de la transition écologique pour l’agriculture et répondre aux défis mondiaux de l’impact des sécheresses sur les grandes cultures. Basée à Moulins-sur-Tardoire, et créée en 2017, l’entreprise emploie plus de 60 collaborateurs dans ses laboratoires établis au sein d’une ferme de 1000 ha, ses bureaux à Lyon et sa filiale au Brésil. La technologie propriétaire d’Elicit Plant est basée sur l’apport exogène de phytostérols, une molécule d’origine végétale, qui augmente la résistance au stress hydrique des plantes. Les essais menés en plein champs ont mis en évidence un gain de rendement de +6 q/ha en moyenne. Elicit Plant a démarré en 2022 la commercialisation en France de sa gamme de produits BEST-a, déclinée notamment sur les cultures de maïs, et obtenu des autorisations de mise sur le marché pour l’Ukraine et le Brésil. Pour en savoir plus : www.elicit-plant.com
Elicit Plant nomme Pam Marrone et Johan de Saegher à son Conseil d’administration
MOULINS-SUR-TARDOIRE, France--(BUSINESS WIRE)--Elicit Plant, une agri-biotech spécialisée dans la résistance des plantes au stress hydrique qui développe une plateforme technologique à base de phytostérols, annonce aujourd’hui la nomination à son Conseil d’administration de Dr. Pam Marrone en tant que Présidente et Dr. Johan de Saegher en tant que membre indépendant. Elicit Plant a été créée en 2017 avec l’ambition de l’ambition de devenir le champion français de la transition écologique pour l’agriculture. Sa plateforme technologique propriétaire fournit aux agriculteurs une solution innovante pour répondre aux défis mondiaux du changement climatique et de l’impact de la sécheresse sur les grandes cultures. Pam Marrone est une serial-entrepreneuse avec plus de 30 d’expérience dans le domaine des solutions biologiques pour l’agriculture. Actuellement, elle exerce en tant que Présidente exécutive de Invasive Species Control Corporation, entreprise qu’elle a cofondée en 2022. Précédemment, elle était Directrice Générale de Marrone Bio Innovations (MBI), une entreprise spécialisée dans l’agriculture bio qu’elle a créée en 2006. En 2013, MBI s’est introduite en bourse au Nasdaq aux Etats Unis. Sous sa direction, l’entreprise a commercialisé 10 produits issus de six ingrédients actifs enregistrés auprès de l’Agence de Protection Environnementale américaine (EPA), et en 2019 a racheté la société ProFarm Technologies spécialisée dans la commercialisation de bio-nutriments produits à partir de déchets de bois. Avant de créer MBI, Pam Marrone a fondé AgraQuest en 1995, entreprise au sein de laquelle elle a été Directrice générale puis Présidente jusqu’en 2006. Personnalité reconnue du secteur, Pam Marrone a été récompensée par de nombreux prix, tels que le “Kathryn C. Hach Award for Entrepreneurial Success,” décerné par l’American Chemical Society, le “Most Admired CEO, Distinguished Career Award” décérné par le Sacramento Business Journal, le prix “Sustie” attribué par l’Ecological Farming Association, et le “Growing Green Award” décerné par le Natural Resources Defense Council (NRDC). Pam Marrone a fondé le Biological Products Industry Alliance, une association professionnelle qui réunit aujourd’hui plus de 100 entreprises. A côté de son rôle de Présidente du Conseil d'administration d’Elicit Plant, Pam Marrone siège au Conseil d’administration de plusieurs entreprises et associations, tels que 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym et la Foundation for Food and Agriculture Research. Johan de Saegher apporte à Elicit Plant une expérience professionnelle de 30 ans dont 17 années dédiées à la protection des cultures agricoles. Il est aujourd’hui Directeur général de Bi-PA, une entreprise spécialisée dans le développement de solutions innovantes pour lutter contres contre les nuisibles agricoles. De 2018 à 2022, Johan de Saegher était Directeur général et Directeur des opérations de Belchim Crop Protection NV, un leader européen de la protection des cultures agricoles basé en Belgique, avec des activités en Amérique du Nord et en Asie. Précédemment, et jusqu’à ce que la société soit rachetée par Eastman Chemical en 2014, Johan de Saegher travaillait chez Taminco (NYSE) où il a successivement exercé les fonctions de Directeur des opérations, Vice-Président Agrosciences et Président Asie/Amérique Latine. Il est actuellement aussi Président de Aphea.bio et siège au Conseil d’administration de Mitsui Agrisciences International. « J’ai été impressionnée par le parcours qu’a réalisé Elicit Plant en si peu de temps. La plateforme technologique propriétaire qu’elle a développé fournit aussi aux agriculteurs une solution naturelle et efficace pour répondre aux défis du changement climatique tout en ayant un impact positif sur l’environnement. J’ai hâte de collaborer avec l’équipe au moment où l’entreprise accélère sa croissance », déclare Pam Marrone. Johan de Saegher poursuit : « C’est un honneur de rejoindre le Conseil d’administration d’Elicit Plant et contribuer à en faire un leader mondial. Grâce à sa technologie innovante, Elicit Plant ouvre de nouvelles perspectives dans le domaine de la gestion du stress abiotique, comme la sécheresse, et dans la protection des rendements agricoles grâce à une optimisation de la réponse naturelle des plantes aux transformations environnementales ». Jean-François Dechant, Président et cofondateur d’Elicit Plant, déclare : « L’arrivée de Pam et Johan est un atout formidable alors que nous nous déployons sur de nouveaux marchés, agrandissons nos laboratoires et diversifions notre portefeuille de produits. Dans une période si stratégique pour Elicit Plant, nous sommes reconnaissants de la confiance qu’ils nous accordent et ravis de la chance qui nous est donnée de bénéficier de leur savoir-faire et de leur track record exceptionnel ». A propos d’Elicit Plant Elicit Plant est une entreprise d’agri-biotech dont l’ambition est de devenir le champion de la transition écologique pour l’agriculture et répondre aux défis mondiaux de l’impact des sécheresses sur les grandes cultures. Basée à Moulins-sur-Tardoire, et créée en 2017, l’entreprise emploie plus de 60 collaborateurs dans ses laboratoires établis au sein d’une ferme de 1000 ha, ses bureaux à Lyon et sa filiale au Brésil. La technologie propriétaire d’Elicit Plant est basée sur l’apport exogène de phytostérols, une molécule d’origine végétale, qui augmente la résistance au stress hydrique des plantes. Les essais menés en plein champs ont mis en évidence un gain de rendement de +6 q/ha en moyenne. Elicit Plant a démarré en 2022 la commercialisation en France de sa gamme de produits BEST-a, déclinée notamment sur les cultures de maïs, et obtenu des autorisations de mise sur le marché pour l’Ukraine et le Brésil. Pour en savoir plus : www.elicit-plant.com
01/10 13:56 EST - businesswire.com
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”) in connection to its merger with 180 Life Sciences Corp. (NASDAQ:ATNF) (the “Merger”) that was completed on November 6, 2020. If you did not exercise your redemption right prior to the completion of the Merger, you may contact Newman Ferrara attorneys Jeffrey Norton (jnorton@nfllp.com) or Benjamin Baker (bbaker@nfllp.com) to discuss this ongoing investigation. Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”) in connection to its merger with 180 Life Sciences Corp. (NASDAQ:ATNF) (the “Merger”) that was completed on November 6, 2020. If you did not exercise your redemption right prior to the completion of the Merger, you may contact Newman Ferrara attorneys Jeffrey Norton (jnorton@nfllp.com) or Benjamin Baker (bbaker@nfllp.com) to discuss this ongoing investigation. Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.
01/09 06:00 EST - pennystocks.com
Using News to Find Penny Stocks to Buy: 3 Tips
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Using News to Find Penny Stocks to Buy: 3 Tips
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
01/06 12:27 EST - pennystocks.com
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
12/31 11:00 EST - pennystocks.com
3 Essential Strategies for Penny Stocks Trading in 2023
Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Essential Strategies for Penny Stocks Trading in 2023
Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.